- Home
- DOMO vs TNGX Comparison
DOMO vs TNGX Comparison
Compare DOMO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMO
- TNGX
- Stock Information
- Founded
- DOMO 2010
- TNGX 2014
- Country
- DOMO United States
- TNGX United States
- Employees
- DOMO N/A
- TNGX N/A
- Industry
- DOMO Computer Software: Prepackaged Software
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- DOMO Technology
- TNGX Health Care
- Exchange
- DOMO Nasdaq
- TNGX Nasdaq
- Market Cap
- DOMO 707.1M
- TNGX 723.2M
- IPO Year
- DOMO 2018
- TNGX N/A
- Fundamental
- Price
- DOMO $13.95
- TNGX $7.77
- Analyst Decision
- DOMO Buy
- TNGX Strong Buy
- Analyst Count
- DOMO 8
- TNGX 6
- Target Price
- DOMO $15.13
- TNGX $10.80
- AVG Volume (30 Days)
- DOMO 663.3K
- TNGX 3.9M
- Earning Date
- DOMO 12-04-2025
- TNGX 11-06-2025
- Dividend Yield
- DOMO N/A
- TNGX N/A
- EPS Growth
- DOMO N/A
- TNGX N/A
- EPS
- DOMO N/A
- TNGX N/A
- Revenue
- DOMO $318,363,000.00
- TNGX $24,296,000.00
- Revenue This Year
- DOMO $2.32
- TNGX $20.42
- Revenue Next Year
- DOMO $2.72
- TNGX N/A
- P/E Ratio
- DOMO N/A
- TNGX N/A
- Revenue Growth
- DOMO N/A
- TNGX N/A
- 52 Week Low
- DOMO $6.01
- TNGX $1.03
- 52 Week High
- DOMO $18.49
- TNGX $9.70
- Technical
- Relative Strength Index (RSI)
- DOMO 47.28
- TNGX 47.05
- Support Level
- DOMO $12.30
- TNGX $6.69
- Resistance Level
- DOMO $13.40
- TNGX $9.39
- Average True Range (ATR)
- DOMO 0.61
- TNGX 0.78
- MACD
- DOMO 0.07
- TNGX -0.13
- Stochastic Oscillator
- DOMO 58.10
- TNGX 35.88
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.